Document is current
Any future updates will be listed below
-
Authors
,
Blagojevic, J.
Bellando-Randone, S.
Abignano, G.
Avouac, J.
Cometi, L.
Czirják, L.
Denton, C. P.
Distler, O.
Frerix, M.
Guiducci, S.
Huscher, D.
Jaeger, V. K.
Lóránd, V.
Maurer, B.
Nihtyanova, S.
Riemekasten, G.
Siegert, E.
Tarner, I. H.
Vettori, S.
Walker, U. A.
Allanore, Y.
Müller-Ladner, U.
Del Galdo, F.
Matucci-Cerinic, M.
- License Information
-
More Information
Article History
Received: 6 September 2018
Accepted: 11 January 2019
First Online: 24 January 2019
Ethics approval and consent to participate
: Ethical approval of DeSScipher OT1 has been obtained from all participating centres’ local ethics committees (project coordinator’s ethics board: Ethics Review board of the Justus-Liebig University Giessen, Germany, approval no 02/13; partners centres ethics review boards: University of Zurich, Switzerland; University of Paris, France; University of Florence Italy; The Second University of Naples, Italy; University of Basel, Switzerland; University College of London, United Kingdom; University of Berlin Charité, Germany; University of Pécs, Hungary; University of Leeds, United Kingdom; and contributors centres ethics boards (additional 21 centres)). Each patient signed a written informed consent form.
: Not applicable.
: The authors report personal fees and non-financial support by the European Community’s Framework Program 7 [FP7-HEALTH-2012.2.4.4-2 Observational trials in rare diseases]; grant agreement no. 305495.OD: Consultancies, speaking fees, and honoraria < $10,000: AnaMar, Bayer, Boehringer Ingelheim, Catenion, CLS Behring, ChemomAb, Roche, GSK, Inventiva, Italfarmaco, Lilly, medac, Medscape, Mitsubishi Tanabe Pharma, MSD, Novartis, Pfizer, Sanofi, UCB Consultancies, speaking fees, and honoraria > $10,000: Bayer, Böhringer. Patents, licenses, or licensing fees: Patent mir-29 for the treatment of systemic sclerosis licensedCPD: Consultancies, speaking fees, and honoraria < $10,000: Actelion, Bayer, Boehringer Ingelheim, Inventiva, Sanofi-Aventis, CSL BehringSV: Consultancies, speaking fees, and honoraria < $10,000: Thermofisher, Abbvie, Boehringer-IngelheimYA: Consultancies, speaking fees, and honoraria < $10,000: Actelion, Boehringer, Roche, Sanofi, Inventiva, Medac, Bayer, BMS, PfizerMMC: Consultancies, speaking fees, and honoraria < $10,000: Actelion, BMS, Pfizer
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
